Tsumura & Co.

4540

JP3535800001

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 11:30:00 31/05/2024 am IST			5-day change	1st Jan Change
3,950 ^JPY	+3.40%		+2.15%	+48.69%

09/05	Tsumura & Co. Announces Dividend for the Full Year Ended March 31, 2024, Scheduled Date to Commence Dividend Payments of June 28, 2024 and Provides Dividend Guidance for the Second Quarter of Fiscal 2025 and Year Ending March 31, 2025	CI
09/05	Tsumura & Co. Provides Consolidated Earnings Guidance for the First Half Fiscal 2025 and Year Ending March 31, 2025	CI

Tsumura Juntendo Inc will Change its Name to Tsumura & Co

March 08, 2013 at 10:30 am IST

Effective March 08, 2013, Tsumura Juntendo Inc will change its name to Tsumura & Co.

Latest news about Tsumura & Co.

Tsumura & Co. Announces Dividend for the Full Year Ended March 31, 2024, Scheduled Date to Commence Dividend Payments of June 28, 2024 and Provides Dividend Guidance for the Second Quarter of Fiscal 2025 and Year Ending March 31, 2025	09/05	CI
Tsumura & Co. Provides Consolidated Earnings Guidance for the First Half Fiscal 2025 and Year Ending March 31, 2025	09/05	CI
Tsumura & Co. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024	06/02	CI
Tsumura & Co. Announces Dividend for the second quarter ended September 30, 2023, Payable on December 5, 2023 and Provides Dividend Guidance for the Full Year Ending March 31, 2024	07/11	CI
Tsumura & Co. Provides Consolidated Earnings Guidance for the First Half Ending September 30, 2023 and Full Year Ending March 31, 2024	03/23/03	CI
Tsumura & Co. Provides Dividend Guidance for the End of Second Quarter and Full Year Ending March 31, 2024	03/23/03	CI
Tsumura's Fiscal 2023 Profit Falls 12.5%; Shares Slip 4%	10/23/10	MT
Tsumura & Co. Reports Earnings Results for the Full Year Ended March 31, 2023	09/23/09	CI
Tsumura & Co. Provides Consolidated Financial Guidance for the First Half and Full Year Ending March 31, 2024	09/23/09	CI
Tsumura & Co. Announces Year End Dividend for the Fiscal Year Ended March 31, 2023, and Provides Second Quarter and Year End Dividend Forecast for the Fiscal Year Ending March 31, 2024	09/23/09	CI
Kontafarma China Unit to Sell 66% Equity Interest of Shaanxi Unisplendour for 168.2 Million Yuan; Shares Slip 7%	14/23/14	MT
Robit, Inc. announced that it has received ¥499 million in funding from Tsumura & Co.	20/23/20	CI
Tsumura & Co. Provides Dividend Guidance for the Full Year Ending March 31, 2023	03/23/03	CI
Tsumura & Co. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023	03/23/03	CI
Tsumura & Co. Announces Dividend for the Period Ended September 30, 2022, Payable on December 5, 2022 and Provides Dividend Guidance for the Full Year Ending March 31, 2023	04/22/04	CI
Tsumura & Co. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023	04/22/04	CI
Tsumura & Co. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023	05/22/05	CI
Tsumura & Co. Provides Consolidated Earnings Guidance for the First Half and Fiscal Year Ending March 31, 2023	05/22/05	CI
Tsumura & Co. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023	10/22/10	CI
Tsumura & Co. Provides Consolidated Earnings Guidance for the First Half and Fiscal Year Ending March 31, 2023	10/22/10	CI
Tsumura & Co. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2022	04/22/04	CI
Tsumura & Co. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2022	04/22/04	CI
Tsumura & Co. Provides Earnings Guidance for the Year Ending March 31, 2022	05/21/05	CI
Tsumura & Co. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2022	05/21/05	CI
Tsumura & Co's Attributable Profit Climbs 34% in Fiscal Q1	09/21/09	MT

TSUMURA & CO. is a Japan-based company mainly engaged in the manufacture and sale of ethical and general pharmaceuticals. Through its subsidiaries, the Company is also engaged in the procurement, sorting and processing of crude drugs, the manufacture and sale of Chinese herbal extract powders and drug substances, the operation of dispensing pharmacies and the provision of logistics services, as well as the development of pharmaceuticals.

Sector

Pharmaceuticals

Calendar

06/11/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Tsumura & Co.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3,950 JPY

Average target price

5,150 JPY

Spread / Average Target

+30.38%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
TSUMURA & CO.	+48.69%	190.77Cr
ELI LILLY AND COMPANY	+40.73%	74TCr
NOVO NORDISK A/S	+32.83%	60TCr
JOHNSON & JOHNSON	-6.30%	35TCr
MERCK & CO., INC.	+15.15%	32TCr
ABBVIE INC.	+4.05%	28TCr
ASTRAZENECA PLC	+15.00%	24TCr
NOVARTIS AG	+9.78%	21TCr
ROCHE HOLDING AG	-5.52%	21TCr
AMGEN INC.	+6.17%	16TCr

Other Pharmaceuticals

Tsumura & Co.

Equities

4540

JP3535800001

Pharmaceuticals

Tsumura Juntendo Inc will Change its Name to Tsumura & Co

Latest news about Tsumura & Co.

Chart Tsumura & Co.

Company Profile

Income Statement Evolution

Ratings for Tsumura & Co.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals